drugset / Trial / NCT06374901
Tislelizumab Combined With Neoadjuvant Chemotherapy Used in the Perioperative Treatment.
Phase 2
Not yet recruiting
134 enrolled
Xiangdong Cheng
Liaoning Cancer Hospital & Institute · collabShanxi Province Cancer Hospital · collabSichuan Cancer Hospital and Research Institute · collabThe Second Affiliated Hospital of Harbin Medical University · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
To evaluate the efficacy of Tislelizumab in combination with chemotherapy versus chemotherapy in neoadjuvant treatment of patients with MHC-II positive (IHC≥2+) and locally advanced gastric/gastroesophageal junction adenocarcinoma by evaluating the main pathologic response rate (MPR).
Timeline
- Start
- 2024-04-25
- Primary completion
- 2026-03-31
- Completion
- 2028-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tislelizumab | Monoclonal antibody | — | — |